Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab Liquid Formulation Safety and Immunogenicity in Asthma
NCT00500539Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Sep 2008
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Novartis. Primary endpoint: Human Antihuman Antibody. Started Jul 2007; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00500539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500539.